Vasculitis & polymyalgia rheumatica
Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study
Authors' conclusion
Biologics are an effective and rather well-tolerated treatment option for UV that are refractory to conventional therapies.
Study context
- Population
- Patients with hypocomplementemic or normocomplementemic urticarial vasculitis who received at least one biologic, 2008 to 2021therapeutic sequences in 41 patients
- Participants
- 52 patients
- Exposure
- Rituximab vs IL1-targeted therapy vs Anti-IgE
- Rituximabn = 23
- IL1-targeted therapyn = 16
- Anti-IgEn = 13
- Outcome
- Cutaneous response, all biologics
- Follow-up
- Median 25 (IQR 12-43) months
Methodological detailsmulticentre, European, urticarial vasculitis (UV) hypocomplementemic in 24 (59%) cases, Biologics used in median in fifth line of treatment, combined with GC in 75%
- Multicentre
- European
- UV hypocomplementemic in 24 (59%) cases
- Biologics used in median in fifth line of treatment, combined with GC in 75%
Main finding
As reported in the abstract
Complete cutaneous response
40%
Partial cutaneous response
37%
Inadequate cutaneous response
23%
Observational data: associations, not effects.
Further findings
- GC discontinuation achieved
- 34%
Safety
Serious adverse events, mainly infectious
- Patients with serious adverse events
- 7 (17%)
Original publication
Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study. Rheumatology (Oxford). Published 23 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →